Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases.
Kong. Byung Soo BS; Lee. Changhan C; Cho. Young Min YM
Key Findings
- Mitochondrial‑encoded peptides such as MOTS‑c, humanin, and SHLPs influence cellular metabolism and insulin sensitivity.
- MOTS‑c has been studied in relation to both type 1 and type 2 diabetes and age‑related diseases.
- Understanding these peptides could lead to new therapies for diabetes and other aging‑related conditions.
Practical Outcomes
- At present there’s no actionable supplement regimen; the main takeaway is that these peptides are promising targets, so biohackers should watch for upcoming studies that might translate into dosing guidelines or products.
Summary
This review explains that tiny proteins made by mitochondria, like MOTS‑c and humanin, help control how cells use energy and respond to insulin, which matters for diabetes and aging. While it points to their potential as future treatments, it doesn’t give concrete dosing or protocols for everyday use.
Abstract
Mitochondria are complex metabolic organelles with manifold pathophysiological implications in diabetes. Currently published mitochondrial-encoded peptides, which are expressed from the mitochondrial open reading frame of the 12S ribosomal RNA type-c (MOTS-c), 16S rRNA (humanin and short humanin like peptide 1-6 [SHLP1-6]), or small human mitochondrial open reading frame over serine tRNA (SHMOOSE) are associated with regulation of cellular metabolism and insulin action in age-related diseases, such as type 2 diabetes mellitus. This review focuses mainly on recent advances in MOTS-c research with regards to diabetes, including both type 1 and type 2. The emerging understanding of MOTS-c in diabetes may provide insight into the development of new therapies for diabetes and other age or senescence-related diseases.
Study Information
pubmed
2023
2023-02-24T00:00:00.000Z
10.4093/dmj.2022.0333
18
77